*Purpose: Most of the technologies to grow human organs in vitro already exist, but experimentation (and policy development support) will be required to ensure that:

*Methods: 1) ethical boundaries for the experimental testing of human “organogenic pod” tissue development are adopted into policy (organogenic pods consist of all of the major organs from the neck down to the thoracic and abdominopelvic cavities);

2) clinical-grade laboratory facilities are established for clinical trials (ARMI);

3) an experimental incubation system (to be a U.S. trade secret) can support growing pods of primate and eventually human organs practically indefinitely;

4) a genetic subtraction technique (CRISPR) can be combined with “brain on a chip” technology to make organogenic pods;

5) experimental growth acceleration protocols result in accelerated, non-cancerous organogenic pod growth.

Stages 1-2 are already underway (R. Franklin Smith et. al. 2020 policy paper recommendations and ARMI tissue foundry)

*Results: Stage 3 will likely require at least 6-9 months of testing;

Stage 4 will likely require at least 5-10 years of testing;Stage 5 may also require 5-10 years of testing

*Conclusions: It is expected that U.S. health insurance providers and independent analysts will recommend to the U.S. public pricing options for how health insurance companies will defray the costs required to grow and maintain organogenic pods between their patients and subscribers.

This poster will also frame a discussion on the advantages of the organ farming approach over current bioprinting trends.

« Back to 2020 American Transplant Congress